Hepatitis Inequalities Study

Health inequality in liver diseases including age, gender, ethnicity and socioeconomic status has been increasingly recognised and potentially hinder hepatitis elimination. Health inequality has significant impact to evaluate the impact diagnostic and treatment uptake rates of chronic viral hepatitis on risk of hepatocellular carcinoma (HCC), hepatic event and liver-related death in patients with chronic hepatitis B and/or C. To overcome the limitation of small prospective cohort study of limited recruitment period, retrieving information from the Clinical Data Analysis and Reporting System (CDARS) from Hospital Authority (HA) will be one of the best way to answer these questions.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Chronic Hepatitis B Blood-Borne Infections Chronic Disease Communicable Diseases DNA Virus Infections Digestive System Diseases Disease Attributes HEPATITIS C VIRUS CHRONIC INFECTION Hepadnaviridae Infections Hepatitis Hepatitis B Hepatitis B, Chronic Hepatitis, Chronic Hepatitis, Viral, Human Infections Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients will be eligible if they have any of these viral markers (HBeAg / HBsAg / HBV DNA / HCV RNA) and/or any of the following diagnosis codes (ICD-9 070-070.9; 348.3, 349.82, 456, 456.2, 456.8, 567.2, 567.8, 570, 571.2, 571.5, 571.6, 572.2, 572.3, 572.4, 789.5) checked or coded in any public hospitals or clinics from 1 January 2000 to 31 March 2024.

Exclusion criteria

Patients with missing age, gender, ethnicity and socioeconomic status
(Subgroup analysis for ethnicity and socioeconomic status) Patients with missing ethnicity and socioeconomic status
Serious medical illnesses or malignancy with life expectancy <1 year

Treatment and study plan

Primary outcomes

Safety

Time frame: From 1 January 2000 to 31 March 2024

Time from diagnosis of hepatitis to treatment.

Secondary outcomes

Safety

Time frame: From 1 January 2000 to 31 March 2024

The composite endpoints of recurrence of hepatic events (e.g. HCC hepatic coma, portal hypertension, variceal bleeding, hepatorenal syndrome).

Study contacts

Contact information is provided by the study sponsor or research team.

Angel Chim, MSc

CONTACT

[email protected]

852-35053759

Grace Wong, MD

CONTACT

[email protected]

852-35054205

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Official study title

Overcoming Inequalities in Health to Eliminate Hepatitis - Real-World Evidence from a Territory-Wide Cohort

Important dates

Study start: 2024
Primary completion: 2030
Study completion: 2031
First posted: Sep 19, 2024
Registry last updated: Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not yet recruiting